ALDX Aldeyra Therapeutics Inc.

6.45
-0.20  -3%
Previous Close 6.65
Open 6.60
Price To book 4.19
Market Cap 97718635
Shares 15,150,176
Volume 187,322
Short Ratio 0.13
Av. Daily Volume 1,019,947

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171128833
  2. 8-K - Current report 171128640
  3. 8-K - Current report 171095925
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171093302
  5. 8-K - Current report 171092607

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data released September 11, 2017 - noted statistically and clinically significant activity.
ADX-102
Dry eye syndrome
Phase 2b data released June 14 2017 - primary endpoint not met. However, Phase 3 trial is planned for 1H 2018.
ADX-102
Allergic conjunctivitis
Phase 3 trial initiation announced April 27, 2017 with data due 2H 2018.
ADX-102
Noninfectious anterior uveitis
Phase 3 trial initial data due 2H 2018.
ADX-102
Sjögren-Larsson Syndrome (SLS)

Latest News

  1. Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day
  2. Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting
  3. Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?
  4. /C O R R E C T I O N -- Aldeyra Therapeutics, Inc./
  5. Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
  6. Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference
  7. Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
  8. Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
  9. [$$] Clinical Development News, Sept. 11-15
  10. Today's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals
  11. Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
  12. Today's Research Reports on Stocks to Watch: Aldeyra Therapeutics and Aethlon Medical
  13. Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers
  14. Aldeyra Therapeutics' stock soars after positive results of dry eye disease treatment
  15. Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
  16. Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Dry Eye Disease Phase 2a Clinical Trial
  17. Aldeyra Therapeutics Announces Second Quarter 2017 Financial Results
  18. Investor Network: Aldeyra Therapeutics, Inc. to Host Earnings Call
  19. Aldeyra Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
  20. Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2017 Financial Results

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171128833
  2. 8-K - Current report 171128640
  3. 8-K - Current report 171095925
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171093302
  5. 8-K - Current report 171092607
  6. 424B5 - Prospectus [Rule 424(b)(5)] 171090154
  7. 8-K - Current report 171090063
  8. 8-K - Current report 171080042
  9. 8-K - Current report 171013250
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011545